C92-C00

Acute myeloblastic leukemia, not having achieved remission

## Overview of Acute Myeloblastic Leukemia (AML) Acute myeloblastic leukemia (AML), also known as acute myeloid leukemia, is a rapidly progressing cancer of the blood and bone marrow. It is characterized by the uncontrolled proliferation and accumulation of abnormal, immature myeloid cells (blasts) in the bone marrow, peripheral blood, and sometimes other tissues. These abnormal cells interfere with the production of healthy blood cells, leading to a deficiency of red blood cells, white blood cells, and platelets. ### Not Having Achieved Remission The designation "not having achieved remission" for C92.00 signifies that the disease is currently active. This can mean either: * **Newly Diagnosed:** The patient has recently been diagnosed with AML and has not yet undergone or completed initial treatment aimed at achieving remission. * **Refractory Disease:** The patient has received induction chemotherapy but did not achieve a complete remission (CR). This means the bone marrow still contains more than 5% blasts, or there is evidence of extramedullary leukemia, or peripheral blood counts have not recovered sufficiently. * **Early Relapse/Persistent Disease:** While C92.02 specifically covers 'in relapse', C92.00 might sometimes encompass persistent disease states where remission was never fully established or was very short-lived. ### Pathophysiology AML originates from somatic mutations in hematopoietic stem cells or myeloid progenitor cells, leading to a block in differentiation and enhanced self-renewal. This results in the accumulation of myeloblasts, which are functionally immature and unable to perform normal blood cell functions. The excessive number of blasts crowds out normal hematopoietic cells in the bone marrow, leading to pancytopenia and its associated clinical manifestations. ### Clinical Significance C92.00 represents a critical and often life-threatening stage of AML. Treatment typically involves intensive chemotherapy regimens (e.g., "7+3" regimen), with the goal of achieving a complete remission. Failure to achieve remission often necessitates alternative or more intensive therapies, such as high-dose chemotherapy followed by allogeneic hematopoietic stem cell transplantation, or enrollment in clinical trials for novel agents. Prognosis is generally poorer for patients who do not achieve remission after initial therapy, highlighting the urgency and aggressiveness of treatment required.

Clinical Symptoms

Fatigue and weakness (due to anemia)
Shortness of breath (due to anemia)
Frequent or severe infections, fever (due to neutropenia/leukopenia)
Easy bruising or bleeding, petechiae, purpura (due to thrombocytopenia)
Bone and joint pain (due to marrow expansion by blasts)
Swollen lymph nodes (less common than in ALL, but can occur)
Enlarged liver (hepatomegaly) or spleen (splenomegaly)
Loss of appetite and unintended weight loss
Gingival hyperplasia (especially in monocytic AML subtypes)
Skin lesions (leukemia cutis, often purplish lumps or spots)
Headache, vision problems, seizures (rare, due to central nervous system involvement)

Common Causes

Most cases of AML are 'de novo' with no identifiable cause, likely stemming from random genetic mutations.
**Genetic Syndromes:** Individuals with certain inherited genetic disorders have an increased risk, including Down syndrome, Fanconi anemia, Bloom syndrome, Ataxia-telangiectasia, Li-Fraumeni syndrome, and Neurofibromatosis type 1.
**Exposure to Chemicals:** Prolonged exposure to certain chemicals, particularly benzene, is a known risk factor.
**Previous Cancer Treatment (Therapy-Related AML - t-AML):** Prior exposure to chemotherapy (especially alkylating agents and topoisomerase II inhibitors) or radiation therapy for other cancers can increase the risk of developing AML years later.
**Other Hematologic Disorders:** Progression from pre-existing myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN) such as polycythemia vera, essential thrombocythemia, or primary myelofibrosis.
**Smoking:** Tobacco smoking has been linked to an increased risk of AML.
**Advanced Age:** The incidence of AML increases with age, with the median age at diagnosis being around 68 years.
**Ionizing Radiation Exposure:** High-dose radiation exposure (e.g., atomic bomb survivors, nuclear accident victims) significantly increases AML risk.

Documentation & Coding Tips

Clearly document the diagnosis of Acute Myeloid Leukemia (AML) and explicitly state the current remission status, especially 'not having achieved remission'. Specify the subtype if known.

Example: PATIENT: 68 y/o male with confirmed Acute Myeloblastic Leukemia (FAB M2 subtype, FLT3-ITD positive) not having achieved remission despite induction chemotherapy with 7+3 regimen. Currently receiving palliative care due to refractory disease. Patient presents with worsening fatigue (common complication, impacting ADLs) and persistent neutropenic fever. Assessment confirms AML, not in remission, with associated pancytopenia and febrile neutropenia (D70.9). Current treatment plan involves supportive care, including broad-spectrum antibiotics for infection, and continued monitoring. Status: Not in remission, refractory. Patient is eligible for HCC 19 due to active leukemia and high resource utilization.

Billing Focus: Explicitly stating 'not having achieved remission' and documenting the specific AML subtype and any relevant molecular markers (e.g., FLT3-ITD positive) supports medical necessity and accurate coding. Concurrently documenting complications (e.g., febrile neutropenia D70.9) and active management of those complications is crucial for E/M leveling.

Detail all current treatments, including chemotherapy regimens, radiation, stem cell transplantation status (if applicable), and supportive care measures, linking them to the active disease state.

Example: PATIENT: 55 y/o female with Acute Myeloblastic Leukemia (AML), post-induction chemotherapy (Cytarabine/Daunorubicin) with persistent blasts in bone marrow biopsy (20%), confirming not in remission. Currently admitted for re-induction chemotherapy (FLAG regimen) to attempt remission induction. Also receiving aggressive supportive care including daily transfusions for severe anemia (D64.9) and thrombocytopenia (D69.6) and prophylactic antifungals (B37.9). Patient continues to experience significant treatment-related nausea/vomiting (R11.2) and mucositis (K12.1). The complexity of ongoing chemotherapy and management of severe hematologic toxicities clearly reflects the active, aggressive nature of the AML not in remission. This documentation supports both the primary diagnosis and the intensive care required.

Billing Focus: Documenting specific chemotherapy regimens (e.g., 'FLAG regimen'), transfusion support (P90.9), and management of treatment side effects (e.g., R11.2, K12.1) justifies the level of service (e.g., high-level E/M, prolonged services, chemotherapy administration CPTs). Linking these interventions directly to the 'AML not in remission' ensures medical necessity.

Document all signs, symptoms, and complications directly attributable to the active leukemia and its treatment, ensuring explicit linkage.

Example: PATIENT: 72 y/o male, history of AML (not in remission), presents with new onset severe epistaxis (R04.0) and petechiae (R23.3) due to profound thrombocytopenia secondary to active marrow infiltration by leukemia cells (D69.6). Also reports persistent fatigue (R53.81) and shortness of breath (R06.02) related to severe anemia (D64.9), requiring PRBC transfusions. His AML, not in remission, is causing significant bone marrow failure. The patient's functional status is significantly impaired due to these symptoms, requiring assistance with ADLs. Documentation clearly links these secondary conditions (epistaxis, petechiae, anemia, thrombocytopenia) as 'due to' or 'secondary to' the primary diagnosis of AML, not in remission. This clarifies the causal relationship and medical necessity for intervention.

Billing Focus: Explicitly linking symptoms (epistaxis R04.0, petechiae R23.3, fatigue R53.81, dyspnea R06.02) and complications (thrombocytopenia D69.6, anemia D64.9) to the 'AML, not in remission' strengthens medical necessity for diagnostic tests, procedures, and E/M services. Use of 'due to' or 'secondary to' is crucial.

Relevant CPT Codes

99223 - Initial Hospital Inpatient or Observation Care
AML patients not in remission often require inpatient admission for induction chemotherapy, management of complications like febrile neutropenia, or preparatory regimens for stem cell transplant. This code covers the initial comprehensive evaluation and management.
99233 - Subsequent Hospital Inpatient or Observation Care
AML treatment is prolonged, with patients often staying in the hospital for weeks during induction chemotherapy and subsequent cycles. This code reflects the ongoing daily management of the patient's condition, including monitoring for side effects and disease progression.
38221 - Bone marrow biopsy, needle or trocar
Essential for diagnosing AML, assessing remission status post-treatment, and monitoring disease progression or relapse.
38222 - Bone marrow aspiration
Often performed concurrently with bone marrow biopsy to obtain cellular samples for flow cytometry, cytogenetics, and molecular studies crucial for AML diagnosis and characterization.
96413 - Chemotherapy administration, intravenous infusion, up to 1 hour
Covers the administration of intravenous chemotherapy agents, which is the cornerstone of AML treatment for patients not in remission.
96416 - Chemotherapy administration, intravenous infusion, each additional hour
Many AML induction and re-induction regimens involve prolonged intravenous infusions over several hours or days.
88182 - Flow cytometry; cell enumeration, total count of cells in stained cell suspension
Used in the diagnosis and monitoring of AML to identify blast populations and differentiate from other myeloid disorders. Crucial for assessing remission status.
88237 - Chromosome analysis; count 15-20 cells, 2 karyograms
Cytogenetic abnormalities are common in AML and provide important prognostic information and guide treatment decisions. These analyses help in subtyping AML and assessing risk.